KDM2B Polypeptide Neural Differentiation Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nerve injuries, such as neuroprotective measures and nerve transplantation, have limited effectiveness in promoting neural recovery and tissue regeneration.
Innovation Solution
The use of a synthesized bioactive polypeptide based on histone demethylase KDM2B to regulate the differentiation of mesenchymal stem cells into neurons and promote the regeneration and repair of injured nervous tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional neuroprotective measures and nerve transplantation are used to treat nerve injuries, then some neural protection and repair can be achieved, but the treatment period is long, recovery rate is low, and causing-disability rate is high
Solution Approach 1:
The patent changes the biochemical parameters of stem cells by introducing exogenous KDM2B protein or its active peptides, which demethylate H3K4me3 at neural differentiation gene promoters. This epigenetic parameter change accelerates neural differentiation speed and improves recovery rates while reducing treatment time compared to traditional methods
Solution Approach 2:
The patent uses KDM2B protein and its active peptides as intermediary substances that mediate the differentiation of mesenchymal stem cells into neural cells. This intermediary mechanism provides a more efficient pathway than traditional neuroprotective measures, achieving faster neural regeneration with shorter treatment periods and higher recovery rates
2Reliability
If autogenous/allogenic nerve transplantation is performed to repair injured nerves, then nerve structure can be replaced, but donor tissue is difficult to obtain and secondary injury occurs at donor site
Solution Approach 1:
The patent enables patient's own mesenchymal stem cells to differentiate into neural cells through KDM2B-mediated epigenetic reprogramming. This self-service approach eliminates the need for donor nerve tissue, avoiding secondary injury at donor sites while providing sufficient neural precursor cells for repair
Solution Approach 2:
The patent introduces KDM2B protein or active peptides as an intermediary factor that converts mesenchymal stem cells into neural cells. This intermediary mechanism replaces the need for autogenous/allogenic nerve transplantation, solving the problem of donor tissue scarcity while maintaining high repair effectiveness
3Shape
If transplanted nerves are used to repair injured nerves, then some structural replacement can be achieved, but the transplanted nerves cannot remodel well and cannot recovery the morphology of the tissue structure and the damaged function
Solution Approach 1:
The patent uses living mesenchymal stem cells that are dynamically reprogrammed by KDM2B into neural cells. These dynamically generated neural cells can adapt and remodel to restore tissue morphology and function, unlike static transplanted nerve grafts that fail to remodel effectively
Solution Approach 2:
The patent enables the patient's own stem cells to self-differentiate into neural cells that can naturally remodel and integrate into the injured nerve tissue. This self-service mechanism restores both morphology and function more effectively than transplanted nerves that lack remodelling capability
4Ease of manufacture
If stem cells from apical papilla are used for neural differentiation, then a convenient source of cells is available, but the efficiency of neural differentiation is low and regulatory mechanisms are unclear
Solution Approach 1:
The patent changes the epigenetic parameters of SCAPs by introducing KDM2B, which demethylates H3K4me3 at promoters of neural differentiation genes. This parameter change dramatically improves differentiation efficiency from low baseline levels while SCAPs remain an easily accessible cell source
Solution Approach 2:
The patent introduces KDM2B protein or its active peptides as an intermediary factor that mediates the low-efficiency neural differentiation of SCAPs. This intermediary mechanism activates unclear regulatory pathways, transforming SCAPs into efficient neural precursors while maintaining their advantage as a convenient cell source
Data Source
AI summary
The present invention relates to a bioactive polypeptide synthesized on the basis of histone demethylase, and the use thereof in the neural differentiation process of mesenchymal stem cells. Disclosed in the present invention are possible protein-protein interaction binding sites of histone demethylase KDM2B and histone methylate EZH2, and disclosed are the roles of KDM2B and the bioactive polypeptide synthesized on the basis of the same in the neural differentiation process of mesenchymal stem cells and the tissue regeneration of injured spinal nerves. On this basis, it is concluded that KDM2B and the bioactive polypeptide synthesized on the basis of the same may play a role in promoting the neural differentiation of stem cells from apical papilla and the regeneration of injured spinal nerves.